Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2026 08:00 ET | Source: Neurona Therapeutics

Neurona Presents Updated Data from Ongoing Clinical Trials of Rezanecel (NRTX-1001) Regenerative Cell Therapy in Mesial Temporal Lobe Epilepsy at 2026 American Academy of Neurology (AAN) Annual Meeting

- UNILATERAL MTLE: Low dose resulted in 89% median disabling seizure reduction in participants with MTS during the 7-12-month primary efficacy evaluation period (N=9), and 100% median disabling...
December 08, 2025 08:00 ET | Source: Neurona Therapeutics

Neurona Therapeutics Presents New Long-Term Clinical Data from NRTX-1001 Cell Therapy Trials at 2025 Annual Meeting of the American Epilepsy Society

Neurona Therapeutics Presents New Long-Term Clinical Data from NRTX-1001 Cell Therapy Trials at 2025 Annual Meeting of the American Epilepsy Society
November 18, 2025 16:05 ET | Source: Neurona Therapeutics

Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer

SAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for disorders of the nervous system,...
November 05, 2025 16:05 ET | Source: Neurona Therapeutics

Neurona Therapeutics Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to NRTX-1001 in the Treatment of Drug-Resistant Focal Epilepsy

SAN FRANCISCO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today...
February 20, 2025 12:00 ET | Source: Neurona Therapeutics

Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy

Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy